HRT Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

HRT Financial’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,364	Closed	-$164K	–	3231
2023 Q3	$164K	Buy	14,364 +6	+0%	+$115	﹤0.01%	1874
2023 Q2	$363K	Buy	+14,358	New	+$447K	﹤0.01%	1521
2021 Q1	–	Sell	-8,483	Closed	-$240K	–	3251
2020 Q4	$240K	Buy	+8,483	New	+$220K	﹤0.01%	1416

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's RVNC Position: Q4 2023 in Review

HRT Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 14,364 shares — an estimated $164K sold.

HRT Financial first reported a position in RVNC in Q4 2020 and held it in 3 quarters. The position peaked at $363K in Q2 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

HRT Financial reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
HRT Financial sold 14,364 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $164K.
HRT Financial first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 3 quarters.
HRT Financial's Revance Therapeutics, Inc. position peaked at $363K in Q2 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on HRT Financial's 13F filing for Q4 2023, filed 9 Feb 2024.